Welcome to the OMA Blog

Volume 10 features predictions in obesity medicine, a joint expert review from the OMA and the National Lipid Association , commentary on a weight bias internalization tool for use in pregnancy, and more. Future of Obesity Medicine: Fearless 5-year Predictions for 2029 by OMA Committee Chairs This annual predictions article provides a "time capsule" of thoughts from OMA leaders and members regarding the potential future of obesity medicine in five years. Read Article Evaluating the effectiveness and underlying mechanism of incretin-based treatment for hypothalamic obesity: A narrative review Authors: Dionysios V. Read Article Obesity Pillars ® Journal Obesity Pillars® is an open-access online-only journal published by the Obesity Medicine Association in collaboration with Elsevier.

Obesity Pillars Journal Volume 9 A Summary of Included Articles Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes This study investigated the impact of once-weekly semaglutide treatment after laparoscopic sleeve gastrectomy (LSG) in 29 Japanese patients with type 2 diabetes (T2D). Motivational interviewing for weight management among college students during COVID-19: An exploratory randomized controlled trial During the COVID-19 pandemic, obesity rates among U.S. Read Article Patient perceptions of three-dimensional (3D) surface imaging technology and traditional methods used to assess anthropometry The study discusses the limitations of traditional obesity assessment methods, like Body Mass Index (BMI), which fail to accurately reflect individual body composition variations, and highlights the societal and personal challenges faced by individuals in managing their weight, including stigma and reluctance to engage with healthcare services. It introduces three-dimensional (3D) surface imaging as a non-invasive, precise alternative for assessing human body shape and composition, suggesting it could improve engagement with weight management services by providing a more detailed and less stigmatizing assessment. Read Article Effects of phentermine / topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: A randomized, multicenter, double-blind study While anti-obesity medications such as orlistat and glucagon-like peptide (GLP) receptor agonists may reduce blood pressure, the prescribing information for sympathomimetic agents such as phentermine (PHEN) or Phentermine + Topiramate (PHENT/TPM) warn of potential adverse reactions in raising blood pressure. The study focused on the blood pressure-lowering effects of a phentermine and topiramate combination (PHEN/TPM) in overweight and obese patients, comparing its efficacy to placebo and phentermine alone.